Cured at Any Cost: How America Learned to Pay a Fortune to Avoid Paying Nothing

There is a particular kind of financial logic that governs American healthcare, and it is, by most conventional measures, irrational. The United States spends more per capita on healthcare than any other high-income nation — exceeding $4.5 trillion annually, according to the Centers for Medicare & Medicaid Services — yet consistently ranks near the bottom of peer nations on preventable mortality. The arithmetic is uncomfortable: a country that spends the most is, in measurable terms, preventing the least.

Understanding why requires looking beyond the clinic and into the architecture of incentives, marketing, and cultural conditioning that shapes how Americans think about health in the first place.

The Payment System That Rewards Waiting

At the foundation of this paradox is a reimbursement model that has, for decades, structurally favored intervention over prevention. The fee-for-service framework — still dominant across much of the American insurance landscape — compensates providers for the volume of procedures performed, not for the health outcomes achieved. A cardiologist who performs a coronary bypass generates substantially more billable activity than one who counsels a patient on dietary changes that might prevent the procedure entirely.

This is not a criticism of individual physicians. It is a description of the environment in which they operate. When the financial architecture of a system rewards complexity and procedure, the system tends to produce complexity and procedure. Prevention, by contrast, is largely invisible in billing terms. A disease that never develops generates no claims, no procedures, and no revenue.

The implications extend to patients as well. High-deductible health plans — now carried by more than 55 percent of privately insured Americans, per the Kaiser Family Foundation — create a direct financial disincentive to seek care until symptoms become undeniable. Even when preventive screenings are technically covered at no cost under the Affordable Care Act, the administrative friction, time away from work, and ambient distrust of the healthcare system keep utilization far below recommended levels.

The Pharmaceutical Narrative and the Primacy of Treatment

Beyond insurance structures, the pharmaceutical industry has played a significant role in shaping the cultural imagination around health. Direct-to-consumer advertising — legal in only two countries in the world, the United States being one of them — has spent decades associating wellness with the act of taking something: a pill, an injection, a prescription. The narrative arc of these advertisements is almost universally the same. A person suffers. A product intervenes. The person recovers and returns to their life.

Prevention does not lend itself to this narrative. There is no dramatic moment of recovery when a person avoids a disease they were never diagnosed with. There is no visible transformation. The absence of illness is experientially invisible, which makes it extraordinarily difficult to market — and, as a result, extraordinarily difficult to sustain as a public priority.

According to data from the National Institutes of Health, the United States allocates roughly 3 percent of total healthcare spending to public health and prevention. The remaining 97 percent is directed toward treatment, management, and acute care. This ratio has remained largely stable for decades, even as the evidence base for preventive intervention has grown considerably stronger.

What the Return on Investment Actually Looks Like

The economic case for prevention is not subtle. The Trust for America's Health has estimated that every dollar invested in proven community-based prevention programs yields between $5.60 and $6.20 in downstream savings. The CDC has published similar analyses showing that comprehensive diabetes prevention programs — including structured lifestyle interventions — can reduce the incidence of Type 2 diabetes by more than 58 percent in high-risk populations, at a cost that is a small fraction of the lifetime expense of managing the disease.

Colorectal cancer screening offers another instructive example. A colonoscopy, when performed on schedule, can identify and remove precancerous polyps before they become malignant. The procedure costs, on average, between $800 and $1,500. Treatment for late-stage colorectal cancer, by contrast, can exceed $150,000 — and that figure does not account for lost productivity, caregiver burden, or the personal costs borne by patients and families.

These numbers are widely available. They appear in peer-reviewed literature, government reports, and public health publications. Yet they have not meaningfully shifted the allocation of resources or the behavior of either payers or patients. The question of why demands an honest examination of human psychology alongside systemic critique.

The Behavioral Economics of Invisible Risk

Research in behavioral economics offers a partial explanation. Humans are, by cognitive design, poorly equipped to respond to probabilistic future threats. We discount future harms relative to present inconveniences — a phenomenon known as hyperbolic discounting — which makes the effort of scheduling a preventive appointment feel disproportionately costly compared to the distant and uncertain benefit of avoiding a disease.

This cognitive architecture is not a character flaw. It is an evolved response to a world in which immediate threats demanded immediate attention. But it is profoundly mismatched to the demands of modern chronic disease prevention, which requires sustained behavior change over years or decades in response to risks that may never fully materialize.

Healthcare communicators and public health advocates have been slow to account for this mismatch. Campaigns built around statistical risk reduction — "lower your chance of heart disease by 30 percent" — tend to produce modest behavioral responses, because the framing is abstract and the reward is negative (the absence of something bad) rather than positive (the presence of something good). Reframing prevention as an investment in energy, longevity, and quality of life, rather than as risk mitigation, has shown more promise in recent research — but has not yet penetrated mainstream health messaging at scale.

The Structural Reforms That Could Shift the Balance

Several policy interventions have demonstrated the capacity to move the needle on preventive care utilization. Value-based care models, which tie provider reimbursement to patient health outcomes rather than service volume, have shown early promise in reducing hospitalizations and improving chronic disease management when implemented with fidelity. Community health worker programs, which bring trusted navigators directly into underserved neighborhoods, have consistently improved screening rates and early diagnosis across a range of conditions.

At the individual level, reducing administrative friction — making it easier to schedule, attend, and follow through on preventive appointments — has proven more effective than information campaigns alone. When prevention is made the path of least resistance rather than an act of deliberate self-discipline, participation increases.

None of these solutions are new. Many have been piloted, studied, and validated. What they lack is not evidence but political will, sustained funding, and a healthcare culture that genuinely values what it cannot see.

A System That Can Still Change Course

The preventive paradox is not inevitable. It is the product of choices — choices made by legislators, insurers, employers, and marketers over many decades — and choices can be revisited. The evidence for prevention has never been stronger. The financial case has never been clearer. What remains is the harder work of persuading a system organized around the drama of cure that the quiet discipline of prevention is, in the end, the more powerful act.

For communities, employers, and policymakers willing to look honestly at the numbers, the conclusion is difficult to escape: the most expensive thing America continues to do is wait.